Gyre Therapeutics (NASDAQ:GYRE) Earns Sell (D) Rating from Weiss Ratings

Key Points

• Gyre Therapeutics has received a "sell (D)" rating from Weiss Ratings, while HC Wainwright initiated coverage with a "buy" rating and a price target of $18.00.
• The company's quarterly earnings report showed a missed EPS estimate of $0.02 against a consensus of $0.03 and revenues of $26.77 million, falling short of the $30.80 million expected.
• Institutional investors hold 23.99% of Gyre Therapeutics, with notable increases in stakes from firms like Geode Capital Management and SBI Securities.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright initiated coverage on shares of Gyre Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $18.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $18.00.

Gyre Therapeutics Price Performance

Gyre Therapeutics stock opened at $7.30 on Wednesday. The firm has a market cap of $703.06 million, a price-to-earnings ratio of 730.73 and a beta of 1.78. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $19.00. The firm has a fifty day moving average price of $7.59 and a two-hundred day moving average price of $8.15.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.The company had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million.

Institutional Trading of Gyre Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Gyre Therapeutics by 28.6% in the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company's stock valued at $2,953,000 after acquiring an additional 89,390 shares during the period. SBI Securities Co. Ltd. increased its stake in Gyre Therapeutics by 87.9% in the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company's stock valued at $1,707,000 after acquiring an additional 108,670 shares during the period. American Century Companies Inc. bought a new stake in Gyre Therapeutics in the first quarter valued at about $184,000. Bank of New York Mellon Corp increased its stake in Gyre Therapeutics by 18.7% in the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock valued at $127,000 after acquiring an additional 2,596 shares during the period. Finally, Advantage Alpha Capital Partners LP increased its stake in Gyre Therapeutics by 54.0% in the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock valued at $105,000 after acquiring an additional 4,790 shares during the period. Institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.